Lung Cancer Clinical Trials in Virginia

21 recruiting studies across 1 city

Browse by City

All Trials in Virginia

Phase

Trial	Phase	Sponsor	Dist.
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer	Phase 2/3	SWOG Cancer Research Network	<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors	Phase 2	DualityBio Inc.	<1 mi
Empathic Communication Skills (ECS) Training	N/A	Memorial Sloan Kettering Cancer Center	17 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	Phase 3	National Cancer Institute (NCI)	17 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients	Phase 3	Summit Therapeutics	17 mi
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Phase 3	OncoC4, Inc.	17 mi
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)	Phase 3	Bristol-Myers Squibb	17 mi
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	Phase 1/2	Genmab	17 mi
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Phase 1/2	Hoffmann-La Roche	17 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC	Phase 3	AstraZeneca	17 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma	Phase 3	Children's Oncology Group	17 mi
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)	Phase 2	SCRI Development Innovations, LLC	17 mi
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	Phase 3	Merck Sharp & Dohme LLC	17 mi
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)	Phase 3	Amgen	17 mi
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases	Phase 1	Kiromic BioPharma Inc.	17 mi
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib	Phase 1/2	Genprex, Inc.	17 mi
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer	Phase 3	Hoffmann-La Roche	17 mi
The Vanguard Study: Testing a New Way to Screen for Cancer	N/A	National Cancer Institute (NCI)	17 mi
MYLUNG Consortium Part 3: Observational Study	—	US Oncology Research	27 mi
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations	Phase 3	AstraZeneca	50 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.